Treace Medical Concepts Inc expected to post a loss of 30 cents a share - Earnings Preview

Treace Medical Concepts

04/05/2024 03:09

* Treace Medical Concepts Inc  TMCI.OQ   TMCI.O  is expected
to show a rise in quarterly revenue when it reports  results on
May 7 for the period ending March 31 2024
    * The Ponte Vedra Florida-based  company is expected to
report a
16.3% increase in revenue to $49.065 million from $42.2 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Treace Medical Concepts
Inc is
for a loss of 30 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Treace
Medical
Concepts Inc is $15.00​, above​ its last closing price
of $11.00. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.09       -0.09      -0.10     Missed  -12.9
 Jan. 1 2023   -0.25       -0.26      -0.28     Missed  -7.1
 Jun. 30 2023  -0.23       -0.24      -0.20     Beat    16.1​
 Mar. 31 2023  -0.23       -0.23      -0.23     Met     -0.7
 ​​Dec.        -0.15       -0.14      -0.08     Beat    42.9
 31 2022                                                
 Sep. 30 2022  -0.29       -0.29      -0.22     Beat    23.5​
 Jun. 30 2022  -0.19       -0.20      -0.31     Missed  -51.2
 Mar. 31 2022  -0.21       -0.20      -0.16     Beat    21
 This summary was machine generated May 4 at 02:08 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)